BioCentury | Apr 2, 2021
Product Development

Chinese biotechs look to next-generation CAR T technologies to solve market challenges

...Biotechnology Co. Ltd. and relmacabtagene autoleucel (relma-cel) from JW Therapeutics...
...coming sooner than you think.” James Li, JW Therapeutics...
...said James Li, co-founder and CEO of JW Therapeutics...
BioCentury | Mar 6, 2021
Product Development

The pace of new modality approvals is picking up

...their use to hematological malignancies.In addition, Shanghai-based JW Therapeutics (Shanghai) Co. Ltd....
BioCentury | Dec 19, 2020
Product Development

Chinese biotechs test the waters of novel technology platforms

...to nearly $280 million.Another CAR T company, JW Therapeutics...
BioCentury | Nov 3, 2020
Finance

Nov. 3 Quick Takes: JW lists in Hong Kong; plus Fountain Healthcare’s €125M fund, and EMA reviewing GenSight, Vifor/ChemoCentryx programs

...Staff JW makes public debut on Hong Kong exchangeIn its first day of trading Tuesday, JW Therapeutics...
BioCentury | Aug 20, 2020
Finance

Inhibrx, Harmony debut on NASDAQ as JW, Harbour line up on HKEX

...value to nearly $9.9 billion after raising $213.3 million (see “Big Post-IPO gain for CureVac”).Separately, JW Therapeutics...
BioCentury | Jul 23, 2020
Deals

July 22 Quick Takes: BioNTech raises $512M; plus Vesigen, Quantro, Cullinan, TransThera, JW-Syracuse, AnHeart-NewG

...Investors Back Cullinan’s Asset-Centric Approach” ). Cell therapy co JW gets TCR tech in takeout JW Therapeutics (Shanghai) Co. Ltd....
BioCentury | Jul 17, 2020
Emerging Company Profile

Acepodia: linking antitumor antibodies to immune cells

...The platform, which has the potential for cost savings compared with CAR T therapy, led JW Therapeutics...
...maintain efficacy in the immunosuppressive microenvironment of solid tumors. Under Tuesday’s licensing agreement, Acepodia granted JW Therapeutics (Shanghai) Co. Ltd....
...Patrick Yang and Sonny Hsiao University collaborators: University of California Berkeley Corporate partners: BioMab Inc., JW Therapeutics (Shanghai) Co. Ltd....
BioCentury | Jun 10, 2020
Deals

Deals for leading Chinese immuno-oncology companies: Innovent lands Roche as partner; JW raises $100M

...“HKEX’s Biotech Chapter Shows All the Signs of a Sustainable Market” ). JW’s megaround JW Therapeutics (Shanghai) Co. Ltd.’s...
BioCentury | Jun 25, 2019
Company News

WuXi AppTec raising U.S. profile to counter political attacks

WuXi AppTec plans to raise its profile in the U.S. in the hope that a better understanding of its activities will de-escalate political attacks on the company, co-CEO Edward Hu told BioCentury. While restrictions on...
BioCentury | Jun 14, 2019
Company News

Tessa forms JV with biohub to bring its cell therapies to China

...Inc., now a subsidiary of Celgene Corp. (NASDAQ:CELG), and WuXi AppTec Co. Ltd. (Shanghai:603259) launched JW Biotechnology (Shanghai...
Items per page:
1 - 10 of 23
BioCentury | Apr 2, 2021
Product Development

Chinese biotechs look to next-generation CAR T technologies to solve market challenges

...Biotechnology Co. Ltd. and relmacabtagene autoleucel (relma-cel) from JW Therapeutics...
...coming sooner than you think.” James Li, JW Therapeutics...
...said James Li, co-founder and CEO of JW Therapeutics...
BioCentury | Mar 6, 2021
Product Development

The pace of new modality approvals is picking up

...their use to hematological malignancies.In addition, Shanghai-based JW Therapeutics (Shanghai) Co. Ltd....
BioCentury | Dec 19, 2020
Product Development

Chinese biotechs test the waters of novel technology platforms

...to nearly $280 million.Another CAR T company, JW Therapeutics...
BioCentury | Nov 3, 2020
Finance

Nov. 3 Quick Takes: JW lists in Hong Kong; plus Fountain Healthcare’s €125M fund, and EMA reviewing GenSight, Vifor/ChemoCentryx programs

...Staff JW makes public debut on Hong Kong exchangeIn its first day of trading Tuesday, JW Therapeutics...
BioCentury | Aug 20, 2020
Finance

Inhibrx, Harmony debut on NASDAQ as JW, Harbour line up on HKEX

...value to nearly $9.9 billion after raising $213.3 million (see “Big Post-IPO gain for CureVac”).Separately, JW Therapeutics...
BioCentury | Jul 23, 2020
Deals

July 22 Quick Takes: BioNTech raises $512M; plus Vesigen, Quantro, Cullinan, TransThera, JW-Syracuse, AnHeart-NewG

...Investors Back Cullinan’s Asset-Centric Approach” ). Cell therapy co JW gets TCR tech in takeout JW Therapeutics (Shanghai) Co. Ltd....
BioCentury | Jul 17, 2020
Emerging Company Profile

Acepodia: linking antitumor antibodies to immune cells

...The platform, which has the potential for cost savings compared with CAR T therapy, led JW Therapeutics...
...maintain efficacy in the immunosuppressive microenvironment of solid tumors. Under Tuesday’s licensing agreement, Acepodia granted JW Therapeutics (Shanghai) Co. Ltd....
...Patrick Yang and Sonny Hsiao University collaborators: University of California Berkeley Corporate partners: BioMab Inc., JW Therapeutics (Shanghai) Co. Ltd....
BioCentury | Jun 10, 2020
Deals

Deals for leading Chinese immuno-oncology companies: Innovent lands Roche as partner; JW raises $100M

...“HKEX’s Biotech Chapter Shows All the Signs of a Sustainable Market” ). JW’s megaround JW Therapeutics (Shanghai) Co. Ltd.’s...
BioCentury | Jun 25, 2019
Company News

WuXi AppTec raising U.S. profile to counter political attacks

WuXi AppTec plans to raise its profile in the U.S. in the hope that a better understanding of its activities will de-escalate political attacks on the company, co-CEO Edward Hu told BioCentury. While restrictions on...
BioCentury | Jun 14, 2019
Company News

Tessa forms JV with biohub to bring its cell therapies to China

...Inc., now a subsidiary of Celgene Corp. (NASDAQ:CELG), and WuXi AppTec Co. Ltd. (Shanghai:603259) launched JW Biotechnology (Shanghai...
Items per page:
1 - 10 of 23